tetano
Editor, Senior Moderator
Clin Exp Vaccine Res
. 2022 May;11(2):222-225.
doi: 10.7774/cevr.2022.11.2.222. Epub 2022 May 31.
Epstein-Barr virus reactivation after COVID-19 vaccination in a young immunocompetent man: a case report
Astrid Herzum[SUP] 1 [/SUP], Ilaria Trave[SUP] 1 [/SUP], Federica D'Agostino[SUP] 1 [/SUP], Martina Burlando[SUP] 1 [/SUP], Emanuele Cozzani[SUP] 1 [/SUP], Aurora Parodi[SUP] 1 [/SUP]
Affiliations
Abstract
We present the case of a 24-year-old Caucasian man, who developed a scaly erythematous skin rash after the second dose of coronavirus disease 2019 (COVID-19) vaccination with Comirnaty (BNT162b2, BioNTech/Pfizer; Pfizer, New York, NY, USA) and proved positive for Epstein-Barr virus (EBV) reactivation. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines have been associated with an up-regulated T helper type 1-cell response, possibly favoring an immune system imbalance. Also, EBV reactivation has been postulated after COVID-19 vaccination, but only in the immunosuppressed. Noteworthy we report the first case of EBV viral reactivation associated with cutaneous manifestations in an immunocompetent patient after the COVID-19 vaccine.
Keywords: COVID-19; COVID-19 vaccine; Case report; Epstein-Barr virus; Exanthema.
. 2022 May;11(2):222-225.
doi: 10.7774/cevr.2022.11.2.222. Epub 2022 May 31.
Epstein-Barr virus reactivation after COVID-19 vaccination in a young immunocompetent man: a case report
Astrid Herzum[SUP] 1 [/SUP], Ilaria Trave[SUP] 1 [/SUP], Federica D'Agostino[SUP] 1 [/SUP], Martina Burlando[SUP] 1 [/SUP], Emanuele Cozzani[SUP] 1 [/SUP], Aurora Parodi[SUP] 1 [/SUP]
Affiliations
- PMID: 35799871
- PMCID: PMC9200649
- DOI: 10.7774/cevr.2022.11.2.222
Abstract
We present the case of a 24-year-old Caucasian man, who developed a scaly erythematous skin rash after the second dose of coronavirus disease 2019 (COVID-19) vaccination with Comirnaty (BNT162b2, BioNTech/Pfizer; Pfizer, New York, NY, USA) and proved positive for Epstein-Barr virus (EBV) reactivation. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines have been associated with an up-regulated T helper type 1-cell response, possibly favoring an immune system imbalance. Also, EBV reactivation has been postulated after COVID-19 vaccination, but only in the immunosuppressed. Noteworthy we report the first case of EBV viral reactivation associated with cutaneous manifestations in an immunocompetent patient after the COVID-19 vaccine.
Keywords: COVID-19; COVID-19 vaccine; Case report; Epstein-Barr virus; Exanthema.